Search results
Bisphosphonates. In dogs, bisphosphonates are used as adjuvant therapy for the management of osteosarcoma. They inhibit osteoclast cells (bone busters), which are responsible for bone breakdown.
Medscape - Osteoporosis-specific dosing for Fosamax, Binosto (alendronate), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules,...
Single-dose i.v. zoledronate at 0.25 mg/kg appears to inhibit homeostatic osteolytic activity in healthy, skeletally mature dogs.
Compare Binosto vs Fosamax head-to-head with other drugs for uses, ratings, cost, side effects and interactions.
Dogs, initial dose: 1—2 mg/kg PO Q 8—12 H 39 Increase as needed to: 3—4 mg/kg PO Q 8—12 H 29: Primary adverse effects include, in humans, dry mouth, sedation, behavioral changes, and seizure potentiation; Codeine b Opioid: 0.5—2 mg/kg PO Q 12 H 39: Some suggest dogs only; Pharmacokinetics, but no clinical data, available; Gabapentin ...
This study was a clinical trial, which evaluated the effect of an oral bisphosphonate as a treatment for appendicular osteosarcoma in dogs on outcome (disease free interval and survival) and palliation (pain/symptom control).
29 lip 2000 · The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla.
